CIK 0001640266
- Accelerated filer
- Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 10,086 shares at $3.43 ($34,595)
- 4 Open-market sale President and CEO sold 10,885 shares at $3.43 ($37,336)
- 4 Open-market sale Chief Scientific Officer sold 3,305 shares at $4.26 ($14,079)
- 4 Open-market sale President and CEO sold 11,702 shares at $4.24 ($49,616)
- 4 Open-market sale COO & CBO sold 3,894 shares at $4.25 ($16,550)
- 4 Grant or award Chief Legal Officer acquired 41,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 63,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 51,500 shares (grant or award)
- 4 Open-market sale Chief Scientific Officer sold 5,413 shares at $4.45 ($24,088)
- 4 Open-market sale COO & CBO sold 6,950 shares at $4.45 ($30,928)
- 4 Open-market sale President & CEO sold 16,644 shares at $4.45 ($74,066)
- 4 Open-market sale Chief Legal Officer sold 4,358 shares at $4.45 ($19,393)
- 4 Open-market sale COO & CBO sold 3,087 shares at $5.09 ($15,713)
- 4 Open-market sale Chief Scientific Officer sold 1,191 shares at $5.13 ($6,110)
- 4 Open-market sale COO&CBO sold 6,500 shares at $5.65 ($36,725)
- 4 Open-market sale Chief Legal Officer sold 5,999 shares at $5.82 ($34,914)
- 4 Grant or award Chief Financial Officer acquired 80,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 3 of 16 · 312 filings